<PRE>
[Federal Register: September 11, 2001 (Volume 66, Number 176)]
[Notices]               
[Page 47233-47234]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr11se01-101]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

New Isoform of Tyrosinase-Related Protein (TRP-2) that Contains an 
HLA-A2 Restricted Epitope

Hung T. Khong and Steven A. Rosenberg (NCI)
DHHS Reference No. E-033-01/0 filed 19 Mar 2001
Licensing Contact: Elaine White; 301/496-7056 ext. 282; e-mail: 
<A HREF="mailto:gesee@od.nih.gov">gesee@od.nih.gov</A>

    The current invention embodies the identification of a novel mRNA 
splice variant of the tumor-associated antigen Tyrosinase-Related 
Protein 2 (TRP-2), which is expressed in most melanoma cell lines 
tested. The cDNA encoding this novel TRP-2 isoform is identical to a 
variant of TRP-2 which was previously identified by Rong-fu Wang and 
Steven A. Rosenberg of the NIH (DHHS Reference No. E-183-96; also 
available for licensing for certain fields of use) with the exception 
that the novel isoform contains a 99 base pair insert between exons 6 
and 7, which in turn encodes a 33 amino acid sequence. Specific 
peptides within this 33 amino acid sequence have been identified as 
melanoma antigens by the inventors. These peptides elicit a cytotoxic T 
lymphocyte (CTL) response against melanoma cells in the context of HLA-

[[Page 47234]]

A2, which is widely distributed among patients having malignant 
melanoma. The peptides therefore represent potential vaccines/
immunotherapeutic agents for use against malignant melanoma in HLA-A2-
positive patients.

Genes Related to the Development of Refractory Cancer

S. Mousses, O. Kallioniemi, L. Bubendorf (NHGRI)
DHHS Reference No. E-205-00/0 filed 13 Oct 2000
Licensing Contact: Catherine M. Joyce; 301/496-7056 ext. 258; e-mail: 
<A HREF="mailto:joycec@od.nih.gov">joycec@od.nih.gov</A>

    This application relates to the identification of nucleic acid 
molecules that show temporal expression changes in prostate cancer 
during hormone withdrawal therapy and concomitant tumor regression and 
in the subsequent development of hormone-refractory prostate cancer 
(HPRC). More particularly, the invention relates to methods of 
diagnosing or prognosing the development or progression of prostate 
cancer by detecting abnormalities in from one to several HPRC-related 
genes.
    This work has appeared, in part in Bubendorf et al., 2001, J. of 
the National Cancer Institute 91(20):1758.

    Dated: September 4, 2001.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 01-22791 Filed 9-10-01; 8:45 am]
BILLING CODE 4140-01-P

</PRE>